Organic compounds -- part of the class 532-570 series inventions 04/08

20080097100 - Opiate intermediates and methods of synthesis: Novel opiate intermediate compositions and methods of synthesis that include changing the substitution pattern on the aromatic ring of the pre-Grewe intermediate are provided. The intermediates are morphinane derivatives of formula (10) wherein X is a F or Cl and R is selected from the group consisting of an H,... Agent: Christine M. Rebman Mallinckrodt Inc.

20080097101 - Industrial process for preparation of clopidogrel hydrogen sulphate: An improved process for the manufacture of Clopidogrel starting from 2-(2-thienyl) ethylamine, which eliminates the isolation of an unstable intermediate like 2-(2-thienyl) ethyl formimine by subjecting it to a one pot cyclization to get 4, 5, 6, 7-tetrahydrothieno (3,2-c) pyridine of Formula II and further reacting with halo-compound of Formula... Agent: Blank Rome LLP

20080097102 - Aminotetralin-derived urea modulators of vanilloid vr1 receptor: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.... Agent: Philip S. Johnson Johnson & Johnson

20080097103 - Imidazole-2-thiones: where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as... Agent: Allergan, Inc.

20080097104 - Novel compounds and preparation for montelukast sodium: This invention relates to novel compounds and a process for preparation of montelukast sodium.... Agent: Wpat, PC Intellectual Property Attorneys

20080097105 - Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity: wherein R1, R2, R3, R4, R5, R6, R7a, R7b, W, G1, G2, a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds;... Agent: Theravance, Inc.

20080091021 - Diarylaminofluorene-based organometallic phosphors and organic light-emitting devices made with such compounds: P

20080091022 - Preparation for methscopolamine tannate: Methscopolamine Tannate is prepared from methscopolamine salt and tannic acid salt in aqueous medium. Methscopolamine salt is Methscopolamine bromide or nitrate, preferably methscopolamine bromide, whereas tannic acid salt is an alkali metal salt of tannic acid, preferably potassium salt of tannic acid. The preparation leads to methscopolamine tannate composition having... Agent: Darby & Darby P.C.

20080091023 - Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline: Optically pure 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline tartrate is prepared. The 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline tartrate is particularly useful for preparing solifenacin succinate.... Agent: Kenyon & Kenyon LLP

20080091024 - Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles: Improved processes for preparing substituted 2-(2-pyridylmethyl)sulfinyl-1H-benzimidazoles are disclosed.... Agent: Kenyon & Kenyon LLP

20080086006 - Process for making substituted piperidines: The present invention provides a process for the preparation of substituted piperidines which comprises an asymmetric hydrogenation of vinyl fluoride in the presence of a metal precursor complexed with a chiral mono- or biphosphine ligand.... Agent: Merck And Co., Inc

20080086007 - 2-(pyrazole-1-yl)pyridine derivative: A compound having the formula (1): can be produced with efficiency by using a compound represented by the formula (2): wherein R represents a protected hydroxyl group or a group represented by the formula (3): where R1 represents an alkyl group or an aralkyl group which may be substituted; and... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080086008 - Process for the preparation of a 2-pyridylethylcarboxamide derivative: Process for the preparation of a N-[2-(2-pyridinyl)ethyl]carbox-amide derivative of general formula (I) or a salt thereof 5 Intermediate of general formula (II) Intermediate of general formula (III).... Agent: Ostrolenk Faber Gerb & Soffen

20080081910 - Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives: The present invention provides cycloalkylfused indole, benzothiophene, benzofuran, and indene derivatives, and methods for using them to, for example, treat, prevent and/or ameliorate central nervous system diseases by antagonizing 5-HT1A receptors and modulating serotonin levels.... Agent: Woodcock Washburn LLP/wyeth

20080081911 - Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position: The invention provides a method for producing optically active 3-quinuclidinols having one or more substituted groups at the 2-position; wherein 3-quinuclidinones having one or more substituted groups at the 2-position are reacted with compounds providing hydrogen in the presence of a certain metal complex.... Agent: Wolf Greenfield & Sacks, P.C.

20080081912 - Near-infrared absorptive image-forming composition, ink and electrophotographic toner using the same, and inkjet-recording method, electrophotographic-recording method and near-infrared-ray-reading method using those: wherein L1 is a methine chain composed of 7 methine groups, and L1 may have a substituent but the substituent is not an amino group; R1, R2 and A each independently are an alkyl or cycloalkyl group, which may be substituted; B is a group of atoms necessary for forming... Agent: Buchanan, Ingersoll & Rooney PC